XML 61 R46.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Acquisitions (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jul. 05, 2016 | Sep. 30, 2017 | Apr. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Acquisitions |  |  |  |  |  |  |
Charges to research expense for stock issued in asset acquisition |  |  |  |  |  | $ 4,607 |
Contingent consideration payable |  |  |  |  | $ 25,400 | 269,722 |
Contingent consideration payable, current portion |  |  |  |  | 8,400 | 56,101 |
Contingent consideration payable, non-current portion |  |  |  |  | 17,000 | 213,621 |
Changes in fair value of contingent consideration payable |  |  |  |  | (234,322) | $ 6,760 | $ 4,377
MiaMed Inc |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Asset acquisition, total consideration, stock and cash | $ 6,500 |  |  |  |  |  |
Asset acquisition, cash consideration paid | 1,800 |  |  |  |  |  |
Asset acquisition, potential aggregate deal value | 89,500 |  |  |  |  |  |
Charges to research expense for stock issued in asset acquisition | $ 6,500 |  |  |  |  |  |
MiaMed Inc | Amicus | Common Stock |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Consideration paid in common stock | 825,603 |  |  |  |  |  |
Scioderm |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Enrollment rate (as a percent) |  |  |  | 100.00% |  |  |
Milestone payment |  |  | $ 10,000 |  |  |  |
Scioderm | Amicus | Common Stock |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Consideration paid in common stock |  | 5,900,000 |  |  |  |  |
Callidus |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  | 25,400 |  |
Contingent consideration payable, current portion |  |  |  |  | 8,400 |  |
Contingent consideration payable, non-current portion |  |  |  |  | 17,000 |  |
Callidus | Changes in fair value of contingent consideration payable |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Changes in fair value of contingent consideration payable |  |  |  |  | $ (15,700) |  |
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | $ 83,000 |  |  |  |  |  |

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References No definition available. + Details
Name: | fold_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionContingentConsiderationMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | fold_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The company enrollment percent achieved during the year. + References No definition available. + Details
Name: | fold_BusinessCombinationOfEnrollmentRate
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payment. + References No definition available. + Details
Name: | fold_ContingentConsiderationMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment). + References No definition available. + Details
Name: | fold_PaymentsToAcquireBusinessAssets
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction. + References No definition available. + Details
Name: | fold_ResearchExpenseForStockIssuanceInAssetAcquisition
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |